Heiner Dreismann has been named to the board of directors at Nanogen, the company said this week.
Dreismann is the current CEO of FasTraQ and previously served as president and CEO of Roche Molecular Systems.
Dreismann became a director of Iconix Biosciences last week and last month became a director of GeneNews, formerly ChondroGene.
French gene mapping and bioinformatics company Intragen said last week it has named Emmanuel Martin as director of sales and marketing for its new Genetic Research Services division. He will be responsible for promoting the company’s genotyping services.
Martin spent eight years at Applied Biosystems in France as a sales specialist in genotyping and gene expression and he has a background of six years as a researcher in molecular biology.
DeCode Genetics has appointed Jakob Sigurdsson senior vice president of corporate development. For the past two years Sigurdsson has been CEO and president of the multinational foods company Alfesca, and he previously worked in the US and in Europe for Rohm and Haas.
DeCode said Sigurdsson’s multinational experience should be benefit the company as it works to expand its product development and diagnostics for international pharmaceutical companies.
Scripps Health this week said it has opened a new program, the Translational Science Institute and Genomic Medicine program, and it has named Eric Topol its chief academic officer.
The institute will focus on defining genes that are linked to particular diseases, and then use those findings to pursue new drug therapies.
Topol was chair of the department of cardiovascular medicine at the Cleveland Clinic for 15 years. He was recently named one of the 10 most cited researchers in medicine, and his work on the genomics of coronary disease led to the discovery of the first autosomal dominant mutation inducing coronary disease and heart attack.